ATCT-20BEVACIZUMAB FOR VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA

Abstract

Two big clinical studies have shown that the efficacy of bevacizumab for the treatment of newly diagnosed malignant glioma. Some sub-analysis of these studies showed that bevacizumab may keep long the performance status of the patients suffering from these tumors. While Japan is forecasted to become an aging society, with 20% of over 75 year-old people in 2015, it is important for us to maintain the condition of old people good, even if they are living with malignant tumors. Then, we reviewed the safeness and the efficacy of bevacizumab for keeping the performance status over 2 of elder patients who had newly diagnosed malignant glioma. We studied the patients who were older than 75 years and had surgery in our institution with the diagnosis of malignant glioma histopathologically. After the focal radiotherapy, all patients received 15mg/kg bevacizumab every four week with 150mg/kg temozolomide. We experienced one pulmonary embolism but no major complications related to bevacizumab treatments. Furthermore, our data showed the becacizumab was safe for even very elder patients and kept their condition good when compared to the patients without maintenance therapies.